

Cell line name

WTSli166-A

Purpose

The purpose of this Cell Line Information Pack (CLIP) is to communicate cell line specific information to potential users of the cell line, and to confirm that a User has received it upon the purchase of an EBiSC cell line.

Information

The CLIP may provide a variety of types of information related to an individual cell line. Of particular importance are Third Party Obligations (TPOs), which are ethical or legal obligations of a Depositor related to the use of the cell line. TPOs may impose ethical or legal limitations on the ability of a User to use the cell line, or require steps to be taken before it can be used. TPOs are likely to be:

- Obligations under license to an intellectual property rights (patent) holder, or
- Restrictions on use imposed by the donor of the primary tissue from which the cell line was made.

Third Party Obligations: donor consent provisions

Donor Protection Provisions – Obligations owed to the donors and/or sample custodian

The Material shall not be used for any purposes resulting in the placing in a woman a human embryo which has been created otherwise than by fertilization.

User agrees not to make any attempt to identify the original donors of the Material. User agrees that any genetic or genomic data it generates from use of the Material will be held securely and only used in biomedical research, and will only be made available to third party researchers under a Data Access Agreement at least as stringent as the Data Access Agreement for data from the same Material at the EGA submitted by the Wellcome Trust Sanger Institute ('Sanger'). Sanger encourages submission of genomic data to a managed access repository such as the EGA or dbGAP, with access being restricted to use for biomedical research and subject to a Data Access Agreement at least as stringent as that for data from the same Material at the EGA submitted by Sanger. For the avoidance of doubt, genetic or genomic data from the Material may not be made available on the open internet. User agrees that in any transfer it makes to a third party of any derivatives, modifications or other material derived from the Original Material, in all such cases containing any of the generic material of any of the Original Material, User shall include terms that bind legally the transferee and successive transferees in receipt of any of that genetic material to comply with the donor protection provisions in the paragraph above.

Third Party Obligations: IP or license provisions

iPS-AJ: This EBiSC Cell line was generated under the technology disclosed in patents related to iPS cells which are owned by Kyoto University and are licensable from iPS Academia Japan., Inc. ("iPS AJ"). Commercial user (for-profit entity) acknowledges that, prior to receipt and use of this EBiSC Cell line, such commercial user needs to have an appropriate patent license from iPS AJ even for its research use. Academic user (academic or not-for-profit entity) acknowledges that such academic user does not need a patent license from iPS AJ for its research use, provided, however, that when such academic user uses this EBiSC Cell line for other than its independent research use, such academic user acknowledges that the academic user might need to obtain an appropriate patent license from iPS AJ. For inquiries to iPS AJ, please contact at license@ips-ac.co.jp.

www.EBiSC.org



In case of queries, please get in touch via: Contact@EBiSC.org.

Cell line name

WTSli166-A

Life Tech and successors in title ("LTC") – provider of Cytotune kit used to make iPSCs. Applicable LULL. Limited Use Label License No: 518 CytoTune™ Technology for Products

Notice to Purchaser: This product is authorized for reprogramming methods that involve or pertain to the preparation of iPSCs or related cells. The purchase of this product conveys to the purchaser the limited, non-transferable right to use the purchased amount of product to perform internal use and for educational purposes. No right to resell this product or any of its components, or iPSCs or related cells generated by use of the product, or derivatives thereof (hereafter "the Materials") is conveyed expressly, by implication, or by estoppel. For clarity, purchasers have the right to use third party service providers for generating iPSCs and derivatives for the benefit of such purchasers. Purchasers can deposit the Materials with not-for-profit repositories ("Repositories") and transfer cells to not-for-profit research entities (not affiliated with a for-profit organisation) for their internal research. Such recipient Repositories and not-for-profit research entities are allowed to distribute the Material not-for-financial gain to other users for their internal research.

If the Materials are transferred to other users in accordance with the terms of this label license accompanying the product (hereafter "Label License"), the transferring party should notify recipients of such Materials of these terms by transferring a copy of the Label License to the recipients.

To obtain commercial rights for the sale of the Materials or for a fee-for-service generation of the Materials other than as allowed in paragraph 1 above, purchasers are requested to contact Dनावेक Corporation at cytotune@dnavec-corp.com. For all other commercial applications relating to the use of the Materials, purchasers might be required to contact iPS Academia Japan. Customers may contact iPS Academia Japan either directly at license@ips-ac.co.jp or through Dनावेक Corporation.

Other information

Any publications or public dissemination of results using EBiSC iPSCs should be accompanied by the following acknowledgement: "The EBiSC Bank acknowledges Wellcome Trust Sanger Institute / HipSci as the source of the human induced pluripotent cell line WTSli166-A which was generated with support from the EBiSC project. The EBiSC has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking (JU) under grant agreement n°115582 and from the IMI-2 JU under grant agreement No 821362, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013), European Union's Horizon 2020 research and innovation programme and EFPIA."

The EBiSC Bank acknowledges Wellcome Trust Sanger Institute as the source of the human induced pluripotent cell line which was generated under the Human Induced Pluripotent Stem Cell Initiative funded by a grant from the Wellcome Trust and Medical Research Council, supported by the Wellcome Trust and the NIHR/Wellcome Trust Clinical Research Facility.



In case of queries, please get in touch via: Contact@EBiSC.org.

Cell line name

WTSli166-A

SIGN AND RETURN THIS DOCUMENT WITH YOUR COMPLETED ACCESS AND USE AGREEMENT

User acknowledgement

Please sign below to indicate that you have read and acknowledge the information contained in this CLIP.

Name _____ Position _____

Signature _____ Date _____

www.EBiSC.org



In case of queries, please get in touch via: Contact@EBiSC.org.